After the Texas Northern District Court dismissed Humana’s (HUM) Star ratings lawsuit challenging payment year 2026 ratings, Wells Fargo analyst Stephen Baxter says that that news has no impact on forward star rating cycles and contends that investors had generally assumed the suit had a low probability of success. The firm, which adds that the “only clear benefit would have been incremental cash,” has an Overweight rating with a $348 price target on Humana shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana loses CMS lawsuit, as expected, says Mizuho
- Humana can refile Stars lawsuit at later date, says Barclays
- Humana falls after failing in bid to reverse cuts to Medicare bonus payment
- Humana loses in suit to reverse Medicare bonus payment cut, Bloomberg reports
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says